Kiora Pharmaceuticals
KPRX
6 hedge funds and large institutions have $1.37M invested in Kiora Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
400% more capital invested
Capital invested by funds: $275K → $1.37M (+$1.1M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more funds holding
Funds holding: 4 → 6 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.25M |
| 2 |
Millennium Management
New York
|
+$174K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$34.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$35K |
| 2 |
Morgan Stanley
New York
|
-$17.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1M | +$1.25M | +72 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $166K | – | – | – |
|
|
3
Millennium Management
New York
| $140K | +$174K | +10 | New |
|
|
BFA
4
BlackRock Fund Advisors
San Francisco,
California
| $27K | +$34.8K | +2 | New |
|
|
VIA
5
Vantage Investment Advisors
State College,
Pennsylvania
| $17K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $8K | +$17.4K | +1 | New |
|
|
AIM
7
Acrospire Investment Management
Chicago,
Illinois
| $5K | – | – | – |
|
|
8
Morgan Stanley
New York
| $3K | -$17.4K | -1 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
|
BIM
10
BlackRock Investment Management
Wilmington,
Delaware
| $2K | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$35K | -2 | Closed |
|
KPRX Hedge Fund Activity: Q2 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2016, worth a combined $1.37M — up 400% from $275K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KPRX positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.25M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $35K sold.
- 6 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2016, up from 4 in Q1 2016.
- Funds reported $1.37M of Kiora Pharmaceuticals stock for Q2 2016, up 400% quarter-over-quarter.
- 4 funds opened new Kiora Pharmaceuticals positions in Q2 2016 and 2 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2016 was Sabby Management, an estimated $1.25M added.
- The largest Kiora Pharmaceuticals seller in Q2 2016 was Susquehanna International Group, an estimated $35K sold.
Based on aggregated 13F filings for Q2 2016.